Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 4/20 | 0.59 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | HSD11B1 | P28845 | 4/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL133608 | 0.89 | SPHK2 (0.58) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1548365 | 0.88 | SPHK2 (0.57) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL11259324 | 0.86 | HSD11B1 (0.64) | MEN1KMT2ALMNAHSD11B1POLB | |
| SCHEMBL1548963 | 0.82 | SPHK2 (0.60) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1548764 | 0.81 | SPHK2 (0.51) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1548098 | 0.81 | POLB (0.61) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1548377 | 0.80 | LMNA (0.59) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1548747 | 0.79 | LMNA (0.61) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1548100 | 0.79 | SPHK2 (0.69) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1548985 | 0.79 | SPHK2 (0.52) | SPHK2SPHK1MEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2405751-B1 | SPHINGOSINE KINASE INHIBITOR PRODRUGS | APOGEE BIOTECHNOLOGY CORP (US) | 2015-08-19 | — | — | EP | disclosed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-8557800-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2013-10-15 | — | — | US | disclosed |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120058966-A1 | Sphingosine Kinase Inhibitor Prodrugs | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-03-08 | — | — | US | disclosed |
| US-20120058966-A1 | Sphingosine Kinase Inhibitor Prodrugs | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2012-03-08 | — | — | US | disclosed |
| EP-2405751-A1 | SPHINGOSINE KINASE INHIBITOR PRODRUGS | Apogee Biotechnology Corporation (US) | 2012-01-18 | — | — | EP | disclosed |
| US-8063248-B2 | 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acidisopropylamide; antiproliferative, antiinflammatory agent, angiogenesis inhibitor; sphingolipid-derived signaling pathway; coupling acid or acylhalide of phenyl-adamantane derivatives with aminoalkyl-pyridine | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| US-8063248-B2 | 3-(4-Chloro-phenyl)-adamantane-1-carboxylic acidisopropylamide; antiproliferative, antiinflammatory agent, angiogenesis inhibitor; sphingolipid-derived signaling pathway; coupling acid or acylhalide of phenyl-adamantane derivatives with aminoalkyl-pyridine | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2011-11-22 | — | — | US | disclosed |
| WO-2010105183-A1 | SPHINGOSINE KINASE INHIBITOR PRODRUGS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010105183-A1 | SPHINGOSINE KINASE INHIBITOR PRODRUGS | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-09-16 | — | — | WO | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-07-10 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338961-B2 | Sphingosine kinase inhibitors | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095004-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | SPHK2 2/4885SPHK1 1/4885MEN1 2111/4885 |
| US-20080167352-A1 | Sphingosine Kinase Inhibitors | SPHK1, SPHK2, S1PR1 | SPHK2 2/4885SPHK1 1/4885MEN1 2111/4885 |
| US-20120058966-A1 | Sphingosine Kinase Inhibitor Prodrugs | SPHK1, SPHK2, S1PR1 | SPHK2 2/4885SPHK1 1/4885MEN1 2460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.